FY17 revenues: rather weak
FY17 revenues: rather weakEARNINGS/SALES RELEASES
FACT
DMS released FY17 sales. Revenues reached €27.1m (-9% on a comparable basis), of which €26.5m for DMS Imaging (-10%), €0.5m for DMS Biotech (+18%) and €0 for DMS Wellness.
ANALYSIS
The turnover is clearly disappointing, coming after a 4% decline in H1 17 and 5% over 9 months. Of course, as we have previously mentioned, the level of revenue is hard to estimate on a single quarter, due to the very nature of the Imaging activity, where the signing of a single contract can change the picture overnight, as was the case last year with a €1.9m order in bone densitometry for a Southern European country which contributed to a high comparison basis. The segment thus reported sales down 33%. In this segment, the first sales linked to the agreement with Fujifilm should occur in FY18 after the salesforce is trained. Similarly, the group has decided to slow sales in a North African country due the level of risk associated, which has contributed to the decline of sales in radiology, leading to a 3% decrease in the segment’s sales despite the agreement with Carestream Health partly compensating for this decline.
On the positive side, DMS Imaging has signed a contract in Egypt worth US$1.9 (€1.5m) which should boost FY18 sales. The new segments show a better sales pattern, with DMS Biotech sales up 18% (from a low basis though), with 11 contracts signed in FY17 and an expected significant take-off of sales in FY18, particularly in Europe. Lastly, DMS Wellness should book its first sales in FY18 after the registration process is completed for its cellulite and lymphatic drainage solutions (Celliss). This said, altogether, the overall performance for FY17 is rather weak at the top-line level and it is highly unlikely that the group reaches our current forecast in terms of profits for FY17, again partly because quarterly sales can be very volatile.
IMPACT
We will adjust our numbers/forecasts (most likely to the downside) once the group releases its FY17 results on 30 April.
DIAGNOSTIC MEDICAL SYSTEMS SA, (formerly known as DMS), is a France-based company, which together with its subsidiaries, designs, produces and markets medical imagery devices dedicated to conventional and digital radiology as well as bone densitometry. The Company manufactures a range of products for bone densitometry examination, including the ultrasound imaging system UBIS 5000, Challenger Envision, Stratos dR and Stratos. In the radiology sector, its products include Baccara dRF 43, EOL, Platinum and Da Vinci solutions, among others. In addition, it offers such products as scanners, transcranial Doppler, and Giotto Image mammography system. The Company operates several direct subsidiaries, AXS Medical, Apelem SAS, which manufactures radiology equipment, Medilink SARL, which produces Doppler and bone densitometry devices, Apelem SA, based in Spain, Alpha MOS based in France and one indirect subsidiary, SA Apelem and one indirect affiliated company, Spectrap.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.